Details of the Drug Combinations

General Information of This Drug (ID: DMWV3TZ)

• Drug Name: Finasteride (DMWV3TZ)
• Synonyms: Andozac; Eucoprost; FIT; Finasterida; Finasteridum; Finastid; Finpecia; Propecia; Propeshia; Proscar; Prostide; Cahill May Roberts Brand of Finasteride; Chibro Proscar; Frosst Iberica Brand of Finasteride; Lipha Brand of Finasteride; MSD Brand of Finasteride; MSD Chibropharm Brand of Finasteride; MK 0906; MK 906; MK906; Merck Brand 1 of Finasteride; Merck Brand 2 of Finasteride; Merck Frosst Brand 1 of Finasteride; Merck Frosst Brand 2 of Finasteride; Alternova (TN); Appecia (TN); Chibro-Proscar; Finalo (TN); Finara (TN); Finast (TN); Finasterid (TN); Finasterid IVAX (TN); Finasterida [INN-Spanish]; Finasteridum [INN-Latin]; Finax (TN); Fincar (TN); Finpecia (TN); Gefina (TN); KS-1058; MK-0906; MK-906; Merck Sharp & Dhome Brand 2 of Finasteride; Merck Sharp & Dohme Brand 1 of Finasteride; Propecia (TN); Proscar (TN); Prosteride (TN); YM-152; Finasteride (USP/INN); Finasteride [USAN:INN:BAN]; L-652,931; Proscar, Propecia, Finasteride; N-tert-Butyl-3-oxo-4-aza-5alpha-androst-1-en-17beta-carboxamide; N-tert-Butyl-3-oxo-4-aza-5alpha-androst-1-ene-17beta-carboxamide; N-(2-methyl-2-propyl)-3-oxo-4-aza-5alpha-androst-1-ene-17beta-carboxamide; N-(2-Methyl-2-propyl)-3-oxo-4-aza-5-alpha-androst-1-ene-17-beta-carboxamide; (1S,3aS,3bS,5aR,9aR,9bS,11aS)-N-tert-butyl-9a,11a-dimethyl-7-oxo-1,2,3,3a,3b,4,5,5a,6,9b,10,11-dodecahydroindeno[5,4-f]quinoline-1-carboxamide; (4aR,4bS,6aS,7S,9aS,9bS,11aR)-N-(1,1-dimethylethyl)-4a,6a-dimethyl-2-oxo-2,4a,4b,5,6,6a,7,8,9,9a,9b,10,11,11a-tetradecahydro-1H-indeno[5,4-f]quinoline-7-carboxamide; (4aR,4bS,6aS,7S,9aS,9bS,11aR)-N-(tert-butyl)-4a,6a-dimethyl-2-oxo-2,4a,4b,5,6,6a,7,8,9,9a,9b,10,11,11a-tetradecahydro-1H-indeno[5,4-f]quinoline-7-carboxamide; (5alpha,17beta)-(1,1-Dimethylethyl)-3-oxo-4-azaandrost-1-ene-17-carboxamide; 17beta-(N-tert-butylcarbamoyl)-4-aza-5 alpha-androst-1-en-3-one

Indication

Baldness, male pattern; ICD 11: N.A.; Status: Approved [1]; Benign prostatic hyperplasia; ICD 11: GA90; Status: Approved [2]; Retinopathy; ICD 11: 9B71; Status: Approved [1]

• Therapeutic Class: Antihyperplasia Agents
• Drug Type: Small molecular drug

List of Combinatorial Drugs (CBD) Containing This Drug

1 Investigative Drug Combination(s) Consisting of This drug

Normalized Drug Combination Synergy Score

Synergy scores were normalized using Min-Max Scaling to facilitate visual comparisons.

DrugCom Name	DrugCom ID	Component Drug	Indication	REF
Finasteride + Panobinostat	DCQ7724	Panobinostat	Diffuse intrinsic pontine glioma (Cell Line: DIPG25)	[3]

7 Clinical Trial Drug Combination(s) Consisting of This drug

DrugCom Name	DrugCom ID	Component Drug	Indication	REF
Dutasteride + Finasteride	DCRENW9	Dutasteride	Prostate Cancer	[4]
Flutamide + Finasteride	DCVA5SO	Flutamide	Prostate Cancer	[5]
Tadalafil + Finasteride	DCO099B	Tadalafil	Benign Prostatic Hyperplasia	[6]
Tamsulosin + Finasteride	DCMM90O	Tamsulosin	Benign Prostatic Hyperplasia	[7]
Tamsulosin + Finasteride	DCRY36V	Tamsulosin	Benign Prostate Hyperplasia	[8]
Testosterone + Finasteride	DCYEQ44	Testosterone	Male Hypogonadism	[9]
Minoxidil + Finasteride	DCE29MG	Minoxidil	Androgenetic Alopecia	[10]

References

• [1] Finasteride FDA Label
• [2] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6818).
• [3] Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.
• [4] ClinicalTrials.gov (NCT01342367) Feasibility of Hormones and Radiation for Intermediate or High Risk Prostate Cancer
• [5] ClinicalTrials.gov (NCT00003323) Hormone Therapy in Treating Patients With Prostate Cancer
• [6] ClinicalTrials.gov (NCT01139762) A Study of Tadalafil Use With Finasteride in Men With Enlarged Prostates and Urinary Symptoms
• [7] ClinicalTrials.gov (NCT01534351) Comparison of Finasteride and Tamsulosin for Treatment of Benign Prostatic Hyperplasia (BPH) (MK-0906A-149 AM2)
• [8] ClinicalTrials.gov (NCT01736033) Advanced Benefits of Alpha-blocker Monotherapy on Lower Urinary Tracts Symptoms(LUTS) Patients
• [9] ClinicalTrials.gov (NCT00475501) 5-Alpha Reductase and Anabolic Effects of Testosterone
• [10] ClinicalTrials.gov (NCT05990400) Effectiveness and Safety of Topical Finasteride and Minoxidil Combination Compared to Topical Minoxidil for The Treatment of Male Androgenetic Alopecia